Search

Search results

3115 results found

PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents.

Papp, Kim A, Bruce Strober, Matthias Augustin, Steve Calabro, Anil Londhe, Marc Chevrier, and PSOLAR investigators and Steering Committee. 2012. “PSOLAR: Design, Utility, and Preliminary Results of a Prospective, International, Disease-Based Registry of Patients With Psoriasis Who Are Receiving, or Are Candidates For, Conventional Systemic Treatments or Biologic Agents.”. Journal of Drugs in Dermatology : JDD 11 (10): 1210-7.

Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation.

Bae, Yoon-Soo Cindy, Abby S Van Voorhees, Sylvia Hsu, Neil J Korman, Mark G Lebwohl, Melody Young, Bruce Bebo, Alexa Boer Kimball, and National Psoriasis Foundation. 2012. “Review of Treatment Options for Psoriasis in Pregnant or Lactating Women: From the Medical Board of the National Psoriasis Foundation.”. Journal of the American Academy of Dermatology 67 (3): 459-77.

Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.

The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.

Kimball, Alexa Boer, Andrew P Yu, James Signorovitch, Jipan Xie, Magda Tsaneva, Shiraz R Gupta, Yanjun Bao, and Parvez M Mulani. 2012. “The Effects of Adalimumab Treatment and Psoriasis Severity on Self-Reported Work Productivity and Activity Impairment for Patients With Moderate to Severe Psoriasis.”. Journal of the American Academy of Dermatology 66 (2): e67-76.